Children and teenagers with severe, sometimes life-threatening peanut allergies can reduce their risk from accidental exposure with a new treatment approved Friday by the Food and Drug Administration.
But administering the new treatment, called Palforzia and made by Aimmune Therapeutics (AIMT), is cumbersome and carries its own safety risks, which may deter families and allergists from using it.
Palforzia’s approval was widely expected given the endorsement last September from an FDA advisory panel. The success of the product’s commercial launch is more uncertain but will be closely followed throughout 2020.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect